In addition, sorafenib indirectly suppresses tumor cell proliferation through targeting c-Kit, FLT-3, VEGFR-2/3, PDGFR-β, and other tyrosine kinases, which are involved in tumor angiogenesis [3]. Here, KDR is linked to neoplasm.